NeuroPulse Daily: DMD Trial, Distal Stroke Data, Lecanemab Access
Satellos advances a Phase 2 pediatric DMD trial; Rapid completes DISTALS stroke study; lecanemab gains commercial-insurance access in China; ALS and AD platforms progress.
Shajini
Freenome to Go Public in $1.1B SPAC Deal Backed by Perceptive and RA Capital
Freenome is set to become a public company through a SPAC merger with Perceptive Capital Solutions Corp., a deal valuing the multiomics cancer detection developer at roughly $1.1 billion.
China’s 2026 NRDL Drives Major Breakthroughs in Drug Access
China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the … Read more
German Court Halts Merck’s Keytruda SC in Major Patent Clash
Merck’s plan to introduce a subcutaneous formulation of Keytruda in Germany has been halted after a Munich court issued a preliminary injunction siding with Halozyme’s patent infringement claims.
NeuroPulse Daily: Breakthroughs Across Parkinson’s, Epilepsy and TRS
A high-momentum day across neuroscience as fresh investment, mechanistic innovation, and late-stage readouts tighten the path from discovery to impact.
Weekly Pulse: Policy & Access Rules Rewritten for 2026
The past week delivered a coordinated sequence of moves that, taken together, quietly reset expectations for how global systems will price, approve, pay for, and ultimately adopt innovation in 2026. What distinguished this week was not the volume of news but its consistency: across borders and agencies, decision-makers leaned into a shared posture, broadened access … Read more
Seven NRDL Wins Position Innovent for Volume-Driven Growth in 2025
Innovent Biologics closed out the year with one of its most consequential access wins to date, securing National Reimbursement Drug List (NRDL) inclusion for seven innovative medicines spanning oncology, immunology, metabolism, and rare disease. The breadth of updates underscores how the company’s maturing R&D engine, lifecycle management strategy, and pricing discipline are converging to generate … Read more
G-BA Clears 2026 Launch of Biologic Substitution Rules
Germany has cleared the way for pharmacy-level substitution of prescribed biologics with lower-cost biosimilars starting in 2026.
White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift
The U.S. and U.K. have reached an agreement in principle that lifts U.K. net prices for new innovative medicines by 25 percent, caps VPAG repayments at 15 percent from 2026 onward, and exempts U.K.-origin pharmaceutical and medical goods from Section 232 tariffs.
NeuroPulse Daily: Advancing the Alzheimer’s Battle With Early Detection and Novel Mechanisms
The neurology sector moved on several fronts today, with developments spanning Alzheimer’s diagnostics, mitochondrial-targeted drug programs, neuromodulation evidence standards, glioblastoma immunotherapy, spine portfolio restructuring, and new work on surrogate markers in neurodegeneration. Taken together, the updates reflect a field shifting toward earlier disease interception, biomarker-driven precision, and evidence packages that anticipate payer scrutiny. Alzheimer’s continues … Read more